[Federal Register Volume 85, Number 102 (Wednesday, May 27, 2020)]
[Notices]
[Pages 31751-31752]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11336]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Virtual Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel will take place.
DATES: Open to the public Wednesday, June 24, 2020, from 1:00 p.m. to
2:00 p.m. (Eastern Daylight Time).
ADDRESSES: The address of the open meeting will be online. The phone
number for the remote access is: CONUS: 888-469-2037; OCONUS: 1-517-
308-9287; PARTICIPANT CODE: 8227323. These numbers and the dial-in
instructions will also be posted on the Uniform Formulary Beneficiary
Advisory Panel website at: https://www.health.mil/About-MHS/OASDHA/Defense-Health-Agency/Operations/Pharmacy-Division/Beneficiary-Advisory-Panel.
FOR FURTHER INFORMATION CONTACT: Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: http://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found
on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5
U.S.C., Appendix, as amended), the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
The Panel will review and comment on recommendations made to the
Director, Defense Health Agency, by the Pharmacy and Therapeutics
Committee, regarding the Uniform Formulary.
Purpose of the Meeting: The DoD is publishing this notice to
announce that the following Federal Advisory Committee meeting of the
Uniform Formulary Beneficiary Advisory Panel will take place.
Agenda:
1. Sign-In
2. Welcome and Opening Remarks
[[Page 31752]]
3. Newly Approved Drugs Review
4. Pertinent Utilization Management Issues
5. Panel Discussions and Vote
Meeting Accessibility: Pursuant to 5 U.S.C. 552b, and 41 CFR 102-
3.140 through 102-3.165, and the subject to availability of phone
lines, this meeting is open to the public. Access is limited and will
be provided only to the first 220 people dialing in. There will be 220
lines total: 200 domestic and 20 international, including leader lines.
Written Statements: Pursuant to 41 CFR 102-3.10, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the Uniform Formulary Beneficiary Advisory Panel
about its mission and/or the agenda to be addressed in this public
meeting. Written statements should be submitted to the Uniform
Formulary Beneficiary Advisory Panel's Designated Federal Officer
(DFO). The DFO's contact information can be found in the FOR FURTHER
INFORMATION CONTACT section of this notice. Written comments or
statements must be received by the Uniform Formulary Beneficiary
Advisory Panel's DFO at least five (5) business days prior to the
meeting so they may be made available to the Uniform Formulary
Beneficiary Advisory Panel for its consideration prior to the meeting.
The DFO will review all submitted written statements and provide copies
to all Uniform Formulary Beneficiary Advisory Panel members.
Dated: May 21, 2020.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2020-11336 Filed 5-26-20; 8:45 am]
BILLING CODE 5001-06-P